SB-REG-CDM – innovative stem cell therapy for the treatment of degenerative myelopathy in dogs

Product description

 

SB-REG-CDM is an innovative veterinary biological product developed by Sanford Biotech as a candidate for advanced therapy medicinal product (vATMP) dedicated to the treatment of canine degenerative myelopathy (CDM) in dogs.

The preparation uses a combination of mesenchymal stem cells (MSCs) and glial-restricted progenitors (GRPs), developed on the basis of many years of translational research conducted in collaboration with academic centres in Poland and abroad.

The aim of SB-REG-CDM therapy is to slow down the progression of neurodegenerative diseases in dogs, improve nerve conduction and restore partial motor function in myelin- and neuroinflammatory-based disorders.

Aplication

SB-REG-CDM is intended for dogs with:

  • degenerative myelopathy (CDM) – a disease analogous to human ALS,
  • inflammatory encephalopathies,
  • spinal cord injuries and limb paralysis,
  • demyelinating neuropathies and nerve conduction disorders.

Neurodegenerative diseases in dogs occur mainly in breeds such as German Shepherds, Corgis, Boxers and Huskies. Currently, there is no effective causal treatment, and pharmacological therapies only slow down the progression of the disease.

 

Key benefits

  • Protection of neurons and myelin sheaths thanks to the neurotrophic action of MSC and GRP.
  • Reduction of inflammatory processes in the spinal cord.
  • Improvement of nerve conduction and partial regeneration of motor pathways.
  • Slowing down the progression of the disease and prolonging the period of independent movement of the dog.
  • Increased comfort of life thanks to the reduction of neuropathic pain symptoms.

How it works

SB-REG-CDM contains viable mesenchymal stem cells (MSCs) and glial progenitors (GRPs) of allogenic origin.

After intrathecal, intracanal or intra-arterial administration, these cells:

  • differentiate into glial cells supporting myelination,
  • secrete neurotrophic factors (NGF, BDNF, CNTF),
  • limit the activity of pro-inflammatory cytokines (IL-1β, TNF-α),
  • and activate repair mechanisms in neurons and astrocytes.

Preclinical studies have shown that MSCs and GRPs can delay nerve fibre degeneration and support remyelination in large animal models.

Scientific evidence and safety

The safety and therapeutic potential of GRP and MSCs in the treatment of neurodegenerative diseases have been confirmed in numerous publications co-authored by the Sanford Biotech team:

  • Małysz-Cymborska I. et al. (2018) Scientific Reports, 8: 16490 – MRI-guided transplantation of hydrogel-embedded glial progenitors in large animals. 
  • Małysz-Cymborska I. et al. (2021) Scientific Reports, 11: 6581 – Intra-arterial transplantation of stem cells in large animals. 
  • Stanaszek L. et al. (2021) Cells, 10(11): 2968 – Therapeutic potential of canine glial progenitors in dysmyelinating disease. 
  • Rogujski P. et al. (2024) Int. J. Mol. Sci., 25(19): 10580 – Multisite injections of glial progenitors promoting brain myelination. 

No rejection reactions or adverse neurological effects were observed in any of the studies.

 Note to investors

SB-REG-CDM is Europe's first veterinary cell therapy targeting neurodegenerative diseases in dogs. The product is being developed based on translational technologies and may serve as a bridge to future human therapies, such as ALS (amyotrophic lateral sclerosis) and multiple sclerosis (MS).

The neurology – cell therapy segment is growing globally at a rate of >25% CAGR. In EU countries, the population of dogs predisposed to CDM exceeds 1.5 million, making the project one of the most promising in the Sanford Biotech portfolio.

Related content

 

  • SB-REG-CORTO – MSC therapy in small animal orthopaedics
  • Research on glial progenitors
  • Scientific publications Sanford Biotech

 

Przeczytaj więcej